Scarica l'app Stockscreener
12.44
0.80%
-0.10
Precedente Chiudi:
$12.54
Aprire:
$12.27
Volume 24 ore:
15,636
Relative Volume:
0.14
Capitalizzazione di mercato:
$180.13M
Reddito:
$1.80M
Utile/perdita netta:
$1.76B
Rapporto P/E:
0.1048
EPS:
118.674
Flusso di cassa netto:
$-149.23M
1 W Prestazione:
+0.89%
1M Prestazione:
+2.30%
6M Prestazione:
-11.65%
1 anno Prestazione:
-63.62%
Intervallo 1D:
$12.24
$12.58
Intervallo di 1 settimana:
$12.15
$13.55
Portata 52W:
$10.80
$34.58
Inhibrx Biosciences Inc Stock (INBX) Company Profile
Nome
Inhibrx Biosciences Inc
Settore
Industria
Telefono
(858) 795-4220
Indirizzo
11025 N. TORREY PINES ROAD, SUITE 140, LA JOLLA
Confronta INBX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
INBX
Inhibrx Biosciences Inc
|
12.44 | 174.00M | 1.80M | 1.76B | -149.23M | 118.67 |
|
ONC
Beigene Ltd Adr
|
242.20 | 24.41B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
435.77 | 111.55B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.31 | 42.47M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.39 | 63.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
74.98 | 5.92B | 0 | -153.72M | -103.81M | -2.00 |
Inhibrx Biosciences Inc Stock (INBX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-07-23 | Iniziato | JMP Securities | Mkt Perform |
| 2024-01-23 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-03-16 | Iniziato | SMBC Nikko | Outperform |
| 2021-09-21 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2020-09-14 | Iniziato | Credit Suisse | Outperform |
| 2020-09-14 | Iniziato | Evercore ISI | Outperform |
Mostra tutto
Inhibrx Biosciences Inc Borsa (INBX) Ultime notizie
Inhibrx Slashes Q1 Losses by 45%, Reveals Multiple Clinical Trial Readouts Coming in 2025 - Stock Titan
Inhibrx Reports First Quarter 2025 Financial Results - PR Newswire
Oropharyngeal Cancer Treatment Market Size in 7MM is expected - openPR.com
Larynx Cancer Treatment Market Size in 7MM is expected to grow at a decent CAGR by 2032, estimates DelveInsight - openPR.com
Oropharyngeal Cancer Treatment Market Size in 7MM is expected to grow at a decent CAGR by 2032, estimates DelveInsight - Barchart.com
When the Price of (INBX) Talks, People Listen - news.stocktradersdaily.com
(INBX) On The My Stocks Page - news.stocktradersdaily.com
Inhibrx announces leadership changes as co-founder departs - The Pharma Letter
Inhibrx Biosciences reshuffles leadership, appoints new CSO and President By Investing.com - Investing.com South Africa
Inhibrx Biosciences reshuffles leadership, appoints new CSO and President - Investing.com India
Inhibrx Biosciences Announces Departure Of CSO And Appointments Of New CSO And President - TradingView
Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President - PR Newswire
How the (INBX) price action is used to our Advantage - news.stocktradersdaily.com
JMP maintains Market Perform on Inhibrx stock post-earnings - Investing.com India
Inhibrx Biosciences, Inc. SEC 10-K Report - TradingView
Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results - Yahoo
Inhibrx Cancer Drug Shows Complete Response as Company Posts $1.7B Annual Profit - Stock Titan
Long Term Trading Analysis for (INBX) - Stock Traders Daily
Stocks Rebound as US Government Shutdown Seems Averted - The Globe and Mail
When (INBX) Moves Investors should Listen - Stock Traders Daily
Simpson Thacher Adds Partner From Wilson Sonsini - Law360
A closer look at Inhibrx Biosciences Inc (INBX)’s stock price trends - US Post News
BlackRock, Inc. Increases Stake in Inhibrx Biosciences Inc. - GuruFocus.com
(INBX) Trading Signals - Stock Traders Daily
Inhibrx reports promising ozekibart trial results - MSN
Inhibrx's SWOT analysis: oncology biotech stock faces pivotal year ahead - MSN
Inhibrx’s early colorectal cancer data clouded by patient death - Endpoints News
Inhibrx Biosciences Announces Preliminary Data from the Phase 1 - GuruFocus.com
Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer – Company Announcement - Financial Times
Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer - PR Newswire
How to Take Advantage of moves in (INBX) - Stock Traders Daily
Inhibrx Biosciences enters $150M loan facility - MSN
Regeneron, Illumina invest in Truveta; Inhibrx Bio’s $150M loan - Endpoints News
Inhibrx Biosciences, Inc. Announces Loan Agreement with Oxford Finance LLC - Marketscreener.com
Inhibrx Biosciences Announces Loan Agreement with Oxford Finance - StreetInsider.com
(INBX) Pivots Trading Plans and Risk Controls - Stock Traders Daily
How To Trade (INBX) - Stock Traders Daily
Inhibrx's SWOT analysis: biotech stock faces pivotal year amid clinical trials - Investing.com India
(INBX) Trading Report - Stock Traders Daily
Inhibrx Biosciences' SWOT analysis: oncology firm's stock faces pivotal year By Investing.com - Investing.com Nigeria
Inhibrx Biosciences' SWOT analysis: oncology firm's stock faces pivotal year - Investing.com
2024’s Busiest Dealmakers: Novartis Laps The Field, While Lilly, Sanofi Keep Busy - insights.citeline.com
Inhibrx Biosciences director Jon Faiz Kayyem buys $1.52m in stock - Investing.com Nigeria
Trend Tracker for (INBX) - Stock Traders Daily
The recent drop in prices must have disappointed Inhibrx Biosciences, Inc. (NASDAQ:INBX) institutional investors who own 43% of the shares - Yahoo Finance
institutional investors of Inhibrx Biosciences, Inc. (NASDAQ:INBX) must be disappointed after last week's 15% drop - Simply Wall St
Perceptive Advisors LLC Bolsters Stake in Inhibrx Biosciences Inc - GuruFocus.com
Inhibrx Biosciences Reports Third Quarter 2024 Financial Results - PR Newswire
Wilson Sonsini Knocks Out Claims Against Inhibrx Biosciences in Trade Secrets Verdict - Law.com
Inhibrx Biosciences Inc Azioni (INBX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
17.27%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):